When does vaginal bleeding stop after starting Provera (medroxyprogesterone)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 15, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

When Vaginal Bleeding Stops After Provera

Withdrawal bleeding typically occurs within 3 to 7 days after discontinuing Provera (medroxyprogesterone acetate) therapy, and this bleeding pattern is consistent whether used for secondary amenorrhea or abnormal uterine bleeding. 1

Expected Timeline for Bleeding Cessation

For Oral Provera (Cyclic Use)

  • Withdrawal bleeding begins 3-7 days after stopping the medication and represents the expected therapeutic response 1
  • This applies to both secondary amenorrhea treatment (5-10 mg daily for 5-10 days) and abnormal uterine bleeding management (5-10 mg daily for 5-10 days) 1
  • The bleeding itself typically lasts several days, similar to a normal menstrual period 1

For Depo-Provera (Injectable Contraceptive)

The bleeding pattern differs significantly from oral formulations:

  • Initial irregular bleeding is common and typically improves over 6-12 months of continued use 2, 3
  • In one study, 58% of patients reported bleeding after the first 3 months, declining to only 10% still experiencing slight bleeding at 12 months in the higher dose groups 2
  • By 24 months, amenorrhea (no bleeding) occurred in all women receiving 5 mg or 10 mg daily continuous combined therapy 2
  • For the 150 mg intramuscular injection used as contraception, irregular or excessive menstrual bleeding diminishes with long-term use, with a high percentage becoming amenorrheic over time 3

Acute Bleeding Management with Provera

When Provera is used to stop acute abnormal uterine bleeding (rather than induce withdrawal bleeding):

  • Bleeding cessation occurs rapidly, with a mean time of 2.6 days when using combination therapy of depo-medroxyprogesterone acetate 150 mg IM plus oral medroxyprogesterone acetate 20 mg every 8 hours for 3 days 4
  • All patients in this study stopped bleeding within 5 days 4
  • For chronic fibroid-related menorrhagia treated with monthly Depo-Provera 150 mg, 30% became amenorrheic and 70% showed improvement in bleeding pattern after 6 months 5

Important Clinical Considerations

Breakthrough Bleeding During Continuous Use

  • Breakthrough bleeding or spotting is a common side effect, especially during the first 3-6 months, and generally improves with continued use 6
  • NSAIDs (mefenamic acid 500 mg three times daily or ibuprofen) are first-line treatment for breakthrough bleeding during days of active bleeding only 6, 7

Prior Oral Contraceptive Use

  • Switching directly from oral contraceptives to Depo-Provera significantly reduces bleeding duration in the first 6 months (5.7 days vs. 17.1 days total bleeding) 8
  • This effect does not persist beyond 6 months 8

When to Reassess

  • If withdrawal bleeding does not occur within 3 weeks after completing oral Provera therapy, pregnancy testing is warranted 9
  • Persistent irregular bleeding beyond 3-6 months requires evaluation for underlying pathology including pregnancy, sexually transmitted infections, and uterine conditions (polyps, fibroids) 6, 7, 10

References

Research

Long-term contraception with Depo-Provera: a clinical evaluation.

International journal of fertility, 1980

Research

Medical management of uterine fibroids with medroxyprogesterone acetate (Depo Provera): a pilot study.

Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology, 2004

Guideline

Management of Breakthrough Bleeding with Combined Hormonal Contraceptives

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Management of Breakthrough Bleeding with Mirena IUD

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Depo-Provera in adolescents: effects of early second injection or prior oral contraception.

The Journal of adolescent health : official publication of the Society for Adolescent Medicine, 1995

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Managing HRT-Related Bleeding

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.